| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10414831 | PHARMACOSMOS AS | Stable iron oligosaccharide compound |
Mar, 2029
(4 years from now) | |
| US8815301 | PHARMACOSMOS AS | Stable iron oligosaccharide compound |
Aug, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11633489 | PHARMACOSMOS AS | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant |
Jun, 2036
(12 years from now) | |
Monoferric is owned by Pharmacosmos As.
Monoferric contains Ferric Derisomaltose.
Monoferric has a total of 3 drug patents out of which 0 drug patents have expired.
Monoferric was authorised for market use on 16 January, 2020.
Monoferric is available in solution;intravenous dosage forms.
Monoferric can be used as method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose, treatment of iron deficiency anemia (dia) in adults patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose.
The generics of Monoferric are possible to be released after 22 June, 2036.
Drugs and Companies using FERRIC DERISOMALTOSE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: Treatment of iron deficiency anemia (dia) in adults patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney dise...
Dosage: SOLUTION;INTRAVENOUS
MONOFERRIC family patents
